OHSU

Dr. Blanke joins Knight, brings SWOG clinical trials Share This OHSU Content

Dr. BlankeCharles Blanke, M.D. will join the Knight Cancer Institute in Februry, 2013, serving with the Knight’s team of gastrointestinal cancer specialists.

Dr. Blanke is chair-elect to SWOG (formerly the Southwest Oncology Group), one of the U.S. National Cancer Institute’s five large-scale cooperative groups that test new cancer treatments and prevention programs. SWOG oversees more than $40 million in research annually, and will now be headquartered at the Knight. In addition, multi-year NCI grants worth about $20 million to $25 million annually are expected to move to the Knight.

SWOG has more than 4,000 affiliated physician researchers participating at more than 500 institutions throughout the world, and about 100 clinical trials at any given time.

“The work Knight investigators are doing to pave the way for development of more targeted therapies aimed at curing a variety of cancers based on the specific biology of a patient’s tumor, is a major focus of SWOG research,” said Dr. Blanke.

Dr. Blanke is currenlty vice-president of systemic therapy for the British Columbia Cancer Agency, chief of medical oncology at the University of British Columbia and chair of the Gastrointestinal Stromal Tumor (GIST) Task Force for the NCI’s Gastrointestinal Steering Committee.

He will join several other significant recent Knight recruits, including Lisa Coussens, Ph.D., and Joe Gray, Ph.D.

Want more info about Dr. Blanke’s work? Read the press release.

 

*Article from Knight News blog